416 related articles for article (PubMed ID: 30181760)
1. The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.
Zhao Y; Singh RP
Drugs Context; 2018; 7():212532. PubMed ID: 30181760
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
Wu L; Acón D; Wu A; Wu M
Taiwan J Ophthalmol; 2019; 9(4):216-223. PubMed ID: 31942426
[TBL] [Abstract][Full Text] [Related]
3. Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature.
Chatziralli I; Loewenstein A
Pharmaceutics; 2021 Jul; 13(8):. PubMed ID: 34452097
[No Abstract] [Full Text] [Related]
4. Intravitreal anti-vascular endothelial growth factors, panretinal photocoagulation and combined treatment for proliferative diabetic retinopathy: a systematic review and network meta-analysis.
Fallico M; Maugeri A; Lotery A; Longo A; Bonfiglio V; Russo A; Avitabile T; Pulvirenti A; Furino C; Cennamo G; Barchitta M; Agodi A; Reibaldi M
Acta Ophthalmol; 2021 Sep; 99(6):e795-e805. PubMed ID: 33326183
[TBL] [Abstract][Full Text] [Related]
5. Anti-Vascular Endothelial Growth Factor Injections: The New Standard of Care in Proliferative Diabetic Retinopathy?
Li X; Zarbin MA; Bhagat N
Dev Ophthalmol; 2017; 60():131-142. PubMed ID: 28427072
[TBL] [Abstract][Full Text] [Related]
6. Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab.
Bressler SB; Beaulieu WT; Glassman AR; Gross JG; Jampol LM; Melia M; Peters MA; Rauser ME;
Ophthalmology; 2017 Apr; 124(4):431-439. PubMed ID: 28161147
[TBL] [Abstract][Full Text] [Related]
7. Recent clinically relevant highlights from the Diabetic Retinopathy Clinical Research Network.
Krick TW; Bressler NM
Curr Opin Ophthalmol; 2018 May; 29(3):199-205. PubMed ID: 29528861
[TBL] [Abstract][Full Text] [Related]
8. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Intravitreous Ranibizumab Compared With Panretinal Photocoagulation for Proliferative Diabetic Retinopathy: Secondary Analysis From a Diabetic Retinopathy Clinical Research Network Randomized Clinical Trial.
Hutton DW; Stein JD; Bressler NM; Jampol LM; Browning D; Glassman AR;
JAMA Ophthalmol; 2017 Jun; 135(6):576-584. PubMed ID: 28492920
[TBL] [Abstract][Full Text] [Related]
10. Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
Gross JG; Glassman AR; Liu D; Sun JK; Antoszyk AN; Baker CW; Bressler NM; Elman MJ; Ferris FL; Gardner TW; Jampol LM; Martin DF; Melia M; Stockdale CR; Beck RW;
JAMA Ophthalmol; 2018 Oct; 136(10):1138-1148. PubMed ID: 30043039
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal anti-vascular endothelial growth factor versus panretinal LASER photocoagulation for proliferative diabetic retinopathy: a systematic review and meta-analysis.
Yates WB; Mammo Z; Simunovic MP
Can J Ophthalmol; 2021 Dec; 56(6):355-363. PubMed ID: 33631120
[TBL] [Abstract][Full Text] [Related]
12. Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.
; Gross JG; Glassman AR; Jampol LM; Inusah S; Aiello LP; Antoszyk AN; Baker CW; Berger BB; Bressler NM; Browning D; Elman MJ; Ferris FL; Friedman SM; Marcus DM; Melia M; Stockdale CR; Sun JK; Beck RW
JAMA; 2015 Nov; 314(20):2137-2146. PubMed ID: 26565927
[TBL] [Abstract][Full Text] [Related]
13. Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.
Royle P; Mistry H; Auguste P; Shyangdan D; Freeman K; Lois N; Waugh N
Health Technol Assess; 2015 Jul; 19(51):v-xxviii, 1-247. PubMed ID: 26173799
[TBL] [Abstract][Full Text] [Related]
14. Temporal Trends in the Treatment of Proliferative Diabetic Retinopathy: An AAO IRIS® Registry Analysis.
Gong D; Hall N; Elze T; Sobrin L; Miller JW; Lorch A; Miller JB;
Ophthalmol Sci; 2021 Sep; 1(3):100037. PubMed ID: 36247812
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab for diabetic retinopathy.
Arevalo JF; Garcia-Amaris RA
Curr Diabetes Rev; 2009 Feb; 5(1):39-46. PubMed ID: 19199897
[TBL] [Abstract][Full Text] [Related]
16. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR PROLIFERATIVE DIABETIC RETINOPATHY: A Systematic Review and Meta-Analysis.
Simunovic MP; Maberley DA
Retina; 2015 Oct; 35(10):1931-42. PubMed ID: 26398553
[TBL] [Abstract][Full Text] [Related]
17. Surgical Innovations in the Treatment of Diabetic Macular Edema and Diabetic Retinopathy.
Berrocal MH; Acaba LA; Chenworth ML
Curr Diab Rep; 2019 Sep; 19(10):106. PubMed ID: 31529405
[TBL] [Abstract][Full Text] [Related]
18. Treatment of proliferative diabetic retinopathy with anti-VEGF agents.
Salam A; Mathew R; Sivaprasad S
Acta Ophthalmol; 2011 Aug; 89(5):405-11. PubMed ID: 21294854
[TBL] [Abstract][Full Text] [Related]
19. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
20. American Society of Retina Specialists Clinical Practice Guidelines on the Management of Nonproliferative and Proliferative Diabetic Retinopathy without Diabetic Macular Edema.
Yonekawa Y; Modi YS; Kim LA; Skondra D; Kim JE; Wykoff CC
J Vitreoretin Dis; 2020 Mar; 4(2):125-135. PubMed ID: 34308094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
